Bullish
Pfizer's TUKYSA approved for front-line HER2+ breast cancer treatment.
Pfizer's TUKYSA regimen has received FDA approval as a front-line maintenance treatment for HER2-positive metastatic breast cancer, potentially expanding its market reach. Additionally, the company declared a fourth-quarter 2026 dividend of $0.43 per share, reflecting confidence in its financial position.
Key points
- FDA approves TUKYSA for front-line HER2+ breast cancer maintenance.
- Pfizer declares $0.43 per share dividend for Q4 2026.
Sources
AI-generated from public news sources. Not financial advice.
